Looking back on patient monitoring stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including DexCom (NASDAQ:DXCM) and its peers.

Although DexCom stock has trailed the broader market over the past year, analysts remain bullish about its prospects.

The DJS Law Group reminds investors of a class action lawsuit against DexCom, Inc. ("DexCom" or "the Company") (NASDAQ: DXCM) for violations of §§10 (b) and 20 (a) of the Securities Exchange Act of ...

Since last year, DexCom ( DXCM +5.54%) has faced a series of issues that have sunk its stock price. The medical device ...

Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Québec government for its recent decision to ...

CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered DexCom losses, you mayCLICK HERE or copy and paste the following link into your browser: ...

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is ...

DXCM's strong Q3 growth, expanding CGM coverage and innovation-driven momentum position it for sustained adoption despite rising competition.

Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") filed a class action in the U.S. District Court for the Southern District of New York alleging violations ...

NEW YORK - November 12, 2025 ( NEWMEDIAWIRE) - Levi & Korsinsky, LLP notifies investors in DexCom, Inc. (NASDAQ: DXCM) of a class action securities lawsuit.

Sophie Clarke speaks to Ellen Watson and Beth McDaniel, better known as the Diabetic Duo, about living with type 1 diabetes and inspiring others online ...

Company: DexCom is a medical device company primarily focused on the design, development, and commercialization of continuous glucose monitoring ("CGM") systems for the management of diabetes and ...